OZ439

A Dose-escalation Study to Investigate Safety and Toleration of OZ439

A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265

Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent

Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers

A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection

Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection

OZ439 PhIIa Study in Plasmodium Falciparum: Extended Observation

An open-label, two-part study to determine the absolute bioavailability (BA) of OZ439 using simultaneous intravenous [14C] OZ439 microdose/800 mg oral dosing and to investigate the pharmacokinetics (PK) of OZ439 granules administered as single doses suspended in different volumes and when co-administered with a single dose of Cobicistat, a string CYP3A4 inhibitor, to healthy subjects in fasted state